Startups addressing diabetes, kidney disease, digestive disorders and metabolic conditions can pursue non-dilutive research funding through the National Institute of Diabetes and Digestive and Kidney Diseases Small Business Program.

NIDDK participates in both the NIH SBIR and STTR programmes and supports innovative research by U.S. small businesses where the work has genuine commercial potential.

Current parent-award limits can reach $400,000 for Phase I and $2.5 million for Phase II.

What Areas Does NIDDK Cover?

NIDDK’s mission spans a large range of major chronic diseases and biological systems.

Potential startup opportunities include technologies connected with:

• Diabetes;
• Endocrine and metabolic diseases;
• Obesity and nutrition;
• Digestive diseases;
• Liver conditions;
• Kidney disease;
• Urologic diseases;
• Hematologic conditions within the NIDDK mission.

Fundable technologies may include drugs, biologics, gene and cell therapies, devices, diagnostics, biomarkers, assays, imaging tools, animal or cellular models, software, informatics platforms and technologies that improve clinical research or patient adherence.

How Much Funding Can NIDDK Provide?

Under the current Parent SBIR and STTR announcements, NIDDK normally permits:

Phase I: up to $400,000.

Phase II: up to $2.5 million.

Approved research areas may qualify for awards above the general SBA statutory guidelines.

NIDDK also participates in the later-stage funding programmes.

The Parent Phase IIB Strategic Breakthrough Award currently lists an NIDDK limit of $3 million.

The Parent CRP programme lists an NIDDK limit of $2 million.

NIDDK Wants to See a Commercialisation Plan

NIDDK specifically emphasises strong timelines for commercialisation, future fundraising and regulatory milestones.

Where a company intends to use NIH funding to produce studies supporting an IND, IDE or another regulatory clearance, NIDDK is interested in seeing how formal consultation with the FDA has shaped the development strategy.

This is an important signal for founders.

A strong scientific plan alone may not be sufficient.

Applicants should know what happens after the experiments succeed.

SBIR or STTR?

The Parent SBIR route is suitable where the small business will perform most of the development work.

STTR requires a formal collaboration with an eligible nonprofit research institution.

Both can support early and later-stage research.

However, the clinical-trial rules are different.

Important NIDDK Clinical Trial Rules

NIDDK accepts clinical trials through SBIR and through Phase IIB.

It does not accept clinical trials through the current Parent STTR announcement or the current Parent CRP programme.

Companies developing clinical interventions should therefore speak with NIDDK programme staff before choosing a mechanism.

What Makes an Application Competitive?

Start with an important patient or research problem.

Then show how your innovation provides a measurable improvement.

A diabetes technology might improve glucose control, adherence, manufacturing, diagnosis or treatment accessibility.

A kidney technology could provide earlier disease detection or improve dialysis-related care.

A digestive-health product might introduce a more effective diagnostic or therapeutic pathway.

Whatever the product, the application should contain scientific milestones that correspond with commercial-development milestones.

For regulated technologies, show where FDA interaction fits into the timeline.

For software or digital-health technologies, explain how the company will demonstrate meaningful clinical value and create a sustainable business model.

Application Deadline

The September 2026 submission window has already passed.

The next Parent SBIR and STTR receipt date is January 5, 2027, followed by April 5, 2027.

Visit the official NIDDK Small Business Program page

For U.S. companies developing serious innovations in diabetes, metabolic health, digestive disease or kidney care, NIDDK SBIR/STTR funding can provide the scientific runway needed to reach regulatory, investor and commercial milestones without immediate equity dilution.